Wutah pendapatan taun lumaku: Capricor Therapeutics (CAPR)

Tandha merek capricor.com (CAPR)

The financial stability of Capricor Therapeutics (CAPR) depends on grants and the results of new drug trials. The LTM annual sales growth rate on the GURU.Markets chart reflects revenue dynamics, where the metric level stands at -99.60. The company is currently scaling production to combat Duchenne muscular dystrophy, strictly adhering to bioethical standards and the principles of sustainable laboratory development.

Capricor Therapeutics, Inc. (CAPR): Wutah pendapatan YoY sajrone 12 wulan kepungkur saka 11.02.2024 nganti 18.11.2026

Capricor Therapeutics Inc. (CAPR) - rincian metrik lan laporan keuangan

- rega saham lan target rega konsensus:
- indikator kapitalisasi bursa perusahaan:
Analisis kabeh metrik perusahaan:Capricor Therapeutics, Inc., CAPR
Produk seri Capricor Therapeutics, Inc.

This indicator measures rolling year revenue dynamics, neutralizing quarterly volatility through a daily recalculation of turnover growth rates. Analyzing the YoY sales growth over the last four quarters on GURU.Markets is critical for Capricor Therapeutics (CAPR), as it reflects the transition from a cost-intensive cell technology development phase to a high-margin commercialization stage for approved therapies.